Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Survodutide

Stage Phase 3Stale

Sponsor Boehringer Ingelheim

Route subcutaneous

Class GLP-1/glucagon

Mechanism glucagon receptor and GLP-1 receptor dual agonist

Target glucagon receptor

Target GLP-1 receptor

Sources

publication, as of 2026-06-07Stale

https://pubmed.ncbi.nlm.nih.gov/42253238/

Survodutide, an investigational glucagon receptor-GLP-1 receptor dual agonist, was administered subcutaneously. At week 76, the mean change in body weight from baseline according to the treatment-regimen estimand was -12.2% in the 3.6-mg group, -13.0% in the 6.0-mg group, and -5.4% in the placebo group.

N Engl J Med 2026;395:776-787, PMID 42253238, abstract

registry, as of 2026-03-12Stale

https://clinicaltrials.gov/study/NCT06066515

Protocol section, NCT06066515 SYNCHRONIZE-1, last update posted 2026-03-12

registry, as of 2026-10-29Stale

https://clinicaltrials.gov/study/NCT06077864

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT). Overall status COMPLETED. Phases PHASE3. Lead sponsor Boehringer Ingelheim. Enrollment 5530. Conditions Obesity. This study is open to adults who are at least 18 years old and have a body mass index (BMI) of 27 kg/m2 or more. People can take part if they have cardiovascular or chronic kidney disease. People who have at least 2 health problems related to their weight or risks of cardiovascul

ClinicalTrials.gov NCT06077864 protocol and results modules

registry, as of 2026-08-06Stale

https://clinicaltrials.gov/study/NCT06066528

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight. Overall status COMPLETED. Phases PHASE3. Lead sponsor Boehringer Ingelheim. Enrollment 755. Conditions Obesity; Diabetes Mellitus, Type 2. This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 diabetes and if they are currently being treated only with diet and exercise or with specific diabetes medications. Only people who

ClinicalTrials.gov NCT06066528 protocol and results modules

registry, as of 2026-10-30Stale

https://clinicaltrials.gov/study/NCT07850063

ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Boehringer Ingelheim. Enrollment 600. Conditions Obesity; Metabolic Dysfunction-associated Steatotic Liver Disease. This study is for adults aged 18 years and older who have a type of fatty liver disease called metabolic dysfunction-associated steatotic liver disease (MASLD). People can take part if their body mass index (BMI) is 27 kg/m² or higher, and they have certain heart and blood vessel

ClinicalTrials.gov NCT07850063 protocol and results modules

registry, as of 2026-10-30Stale

https://clinicaltrials.gov/study/NCT07850050

SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Boehringer Ingelheim. Enrollment 600. Conditions Obesity. This study is open to women up to 65 years of age who are living with overweight or obesity and are going through or have finished menopause. People can join this study if they have a Body Mass Index (BMI) of 30 kg/m² or more, or if their BMI is 27 kg/m² or more and they have one

ClinicalTrials.gov NCT07850050 protocol and results modules

registry, as of 2026-10-27Stale

https://clinicaltrials.gov/study/NCT07855900

SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Boehringer Ingelheim. Enrollment 350. Conditions Obesity. This study is open to adults with overweight or obesity. People can join the study if they have a body mass index (BMI) of 30 kg/m² or more, or a BMI of 27 kg/m² or more with at least one weight- related health problem. Participants must not have diabetes, and they must have trie

ClinicalTrials.gov NCT07855900 protocol and results modules

registry, as of 2026-04-30Stale

https://clinicaltrials.gov/study/NCT06214741

A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight. Overall status COMPLETED. Phases PHASE3. Lead sponsor Boehringer Ingelheim. Enrollment 307. Conditions Obesity; Overweight. This study in China is open to adults who are at least 18 years old who are living with overweight or obesity. People with a body mass index (BMI) of 28 kg/m\^2 or higher or 24 kg/m\^2 or higher with at least 1 weight related problem can join the study. The main purpose of this s

ClinicalTrials.gov NCT06214741 protocol and results modules

registry, as of 2026-04-30Stale

https://clinicaltrials.gov/study/NCT06176365

A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease. Overall status COMPLETED. Phases PHASE3. Lead sponsor Boehringer Ingelheim. Enrollment 274. Conditions Obesity. This study is open to adults who are at least 18 years old and have * a body mass index (BMI) of 35 kg/m² or more and at least one health problem related to their weight, or * a BMI of 27 kg/m² or more and at least two health problems related to their weight. People who have ei

ClinicalTrials.gov NCT06176365 protocol and results modules

registry, as of 2026-04-30Stale

https://clinicaltrials.gov/study/NCT06309992

A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD). Overall status COMPLETED. Phases PHASE3. Lead sponsor Boehringer Ingelheim. Enrollment 218. Conditions Obesity; Non-Alcoholic SteatoHepatitis (NASH). This study is open to adults who are at least 18 years old and have * presumed or confirmed NASH together with overweight or obesity and * a body mass index (BMI) of 30 kg/m² or more, or * a BMI of 27 kg/m² and at least one weight-related health problem. People with a history o

ClinicalTrials.gov NCT06309992 protocol and results modules

registry, as of 2023-11-02Stale

https://clinicaltrials.gov/study/NCT04667377

A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight. Overall status COMPLETED. Phases PHASE2. Lead sponsor Boehringer Ingelheim. Enrollment 387. Conditions Obesity. This study is open to adults, aged 18 to 75 years, with overweight or obesity. People with body mass index (BMI) of 27 or higher to join the study. People who have diabetes cannot participate. The purpose of this study is to find out whether a medicine called BI 456906 helps peop Weight Loss of ≥ 5% of Baseline Weight at Week 46 0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation) 60.7 Weight Loss of ≥ 5% of Baseline Weight at Week 46 2.4 mg BI 456906 - Planned Maintenance Treatment 81.0 Weight Loss of ≥ 5% of Baseline Weight at Week 46 3.6 mg BI 456906 - Planned Maintenance Treatment 82.0 Weight Loss of ≥ 5% of Baseline Weight at

ClinicalTrials.gov NCT04667377 protocol and results modules

registry, as of 2021-03-22Stale

https://clinicaltrials.gov/study/NCT03591718

A Study to Test Different Doses of BI 456906 in Patients With Obesity. Overall status COMPLETED. Phases PHASE1. Lead sponsor Boehringer Ingelheim. Enrollment 131. Conditions Obesity. Main objective is to investigate the tolerability of different titration schemes of BI 456906 in otherwise healthy patients with obesity/overweight, and to determine a titration scheme for future studies.

ClinicalTrials.gov NCT03591718 protocol and results modules

registry, as of 2026-03-13Stale

https://clinicaltrials.gov/study/NCT06200467

A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity. Overall status COMPLETED. Phases PHASE1. Lead sponsor Boehringer Ingelheim. Enrollment 110. Conditions Overweight; Obesity. This study is open to adults between 18 and 55 years of age with overweight or obesity. The purpose of this study is to find out whether a medicine called survodutide (BI 456906) has an effect on cardiac safety. When a new medicine is developed, it is important to check whether i

ClinicalTrials.gov NCT06200467 protocol and results modules

registry, as of 2025-01-22Stale

https://clinicaltrials.gov/study/NCT05751226

A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906. Overall status COMPLETED. Phases PHASE1. Lead sponsor Boehringer Ingelheim. Enrollment 88. Conditions Healthy; Obesity. This study is open to adults between 18 and 55 years of age who are living with overweight or obesity. People with a body mass index (BMI) from 27 to 40 kg/m2 can join the study. The main purpose of this study is to find out how a medicine called BI 1820237 is tolerated by peopl

ClinicalTrials.gov NCT05751226 protocol and results modules

registry, as of 2024-08-15Stale

https://clinicaltrials.gov/study/NCT05296733

A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906. Overall status COMPLETED. Phases PHASE1. Lead sponsor Boehringer Ingelheim. Enrollment 82. Conditions Healthy; Liver Diseases; Obesity. This study is open to adults who have different levels of liver problems and adults who are healthy. People with or without overweight or obesity can take part. This study has 2 parts. The purpose of Part 1 is to find out whether having liver problems influences how BI 456906 is

ClinicalTrials.gov NCT05296733 protocol and results modules

registry, as of 2026-05-12Stale

https://clinicaltrials.gov/study/NCT06745284

A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE1. Lead sponsor Boehringer Ingelheim. Enrollment 64. Conditions Obesity. This study is open to adults between 18 and 65 years of age who have obesity. People can join the study if they have a body mass index (BMI) between 30 and 45 km/m². The purpose of this study is to find out whether a medicine called survodutide improves how the body uses energy a

ClinicalTrials.gov NCT06745284 protocol and results modules

registry, as of 2026-06-15Stale

https://clinicaltrials.gov/study/NCT07413913

A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like Injector. Overall status COMPLETED. Phases PHASE1. Lead sponsor Boehringer Ingelheim. Enrollment 56. Conditions Healthy; Obesity. The goal of this study is to find out whether different formulations of survodutide given by different delivery methods is taken up in the body in a similar way. Participants visit the study site regularly. During study visits, the doctors collect information about participants'

ClinicalTrials.gov NCT07413913 protocol and results modules

registry, as of 2026-10-28Stale

https://clinicaltrials.gov/study/NCT07768813

A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or Obesity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE1. Lead sponsor Boehringer Ingelheim. Enrollment 44. Conditions Healthy; Obesity. The main objective of this trial is to establish the bioequivalence of survodutide in a pre-filled syringe (reference product \[formulation A\]) and in a vial (test product \[formulation B2\]) in male and female trial participants who are healthy or otherwise healthy with overwei

ClinicalTrials.gov NCT07768813 protocol and results modules

registry, as of 2026-03-13Stale

https://clinicaltrials.gov/study/NCT06564441

A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity. Overall status COMPLETED. Phases PHASE1. Lead sponsor Boehringer Ingelheim. Enrollment 34. Conditions Overweight; Obesity. This study is open to adults with overweight or obesity who are otherwise healthy. People can join the study if they have a body mass index of 27 to 39.9 kg/m2 and a body weight over 70 kg. The purpose of this study is to find out whether taking multiple doses of BI 456906 influe

ClinicalTrials.gov NCT06564441 protocol and results modules

registry, as of 2025-04-16Stale

https://clinicaltrials.gov/study/NCT05896384

A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Blood. Overall status COMPLETED. Phases PHASE1. Lead sponsor Boehringer Ingelheim. Enrollment 32. Conditions Healthy. This study is open to women with overweight or obesity who are otherwise healthy. Women with a body mass index (BMI) from 27 to 40 kg/m2 can participate. The purpose of this study is to find out whether taking multiple doses of BI 456906 influences the amount of ethinylestradiol

ClinicalTrials.gov NCT05896384 protocol and results modules

registry, as of 2025-04-23Stale

https://clinicaltrials.gov/study/NCT06492135

A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the Body. Overall status COMPLETED. Phases PHASE1. Lead sponsor Boehringer Ingelheim. Enrollment 30. Conditions Overweight; Obesity. This study is open to Chinese adults aged 18 to 60 with overweight or obesity. People can join the study if they have a Body Mass Index from 24 to 40.0 kg/m2. Survodutide is a medicine being developed to help people with overweight or obesity. The purpose of this study is to fin

ClinicalTrials.gov NCT06492135 protocol and results modules

registry, as of 2026-09-09Stale

https://clinicaltrials.gov/study/NCT05202353

A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE1. Lead sponsor Boehringer Ingelheim. Enrollment 29. Conditions Obesity. This study is open to adults with obesity. People with a body mass index (BMI) in the range from 30 to 40 kg/m2 and a body weight of 70 to 150 kg can participate in the study. The purpose of this study is to find out whether treatment with a medicine called BI 456906 changes the

ClinicalTrials.gov NCT05202353 protocol and results modules

Studies

SYNCHRONIZE-1

Registry NCT06066515

Phase Phase 3

Status Completed

Enrollment 726

Start 2023-11-25

Primary completion 2025-12-02

Study completion 2026-02-20

Survodutide 3.6 mg

Dose 3.6 mg

Regimen once weekly

Weeks 76

Comparator placebo

Population adults with obesity, or overweight with at least one obesity-related complication, excluding diabetes

Estimand ITT

percent change in body weight, -12.2 %, week 76Stale

Survodutide 6.0 mg

Dose 6.0 mg

Regimen once weekly

Weeks 76

Comparator placebo

Population adults with obesity, or overweight with at least one obesity-related complication, excluding diabetes

Estimand ITT

percent change in body weight, -13 %, week 76Stale

Placebo

Regimen once weekly

Weeks 76

Population adults with obesity, or overweight with at least one obesity-related complication, excluding diabetes

Estimand ITT

percent change in body weight, -5.4 %, week 76Stale

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

Registry NCT06077864

Phase Phase 3

Status Completed

Enrollment 5530

Start 2023-11-20

Primary completion 2026-06-01

Study completion 2026-06-30

Catalyst Primary completion. 2026-06-01. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

survodutide 3.6 mg

Dose 3.6 mg

Regimen once weekly

Comparator placebo

Population Obesity

survodutide 6.0 mg

Dose 6.0 mg

Regimen once weekly

Comparator placebo

Population Obesity

Placebo

Regimen once weekly

Population Obesity

SYNCHRONIZE™-2

Registry NCT06066528

Phase Phase 3

Status Completed

Enrollment 755

Start 2023-11-27

Primary completion 2025-12-12

Study completion 2026-04-01

Catalyst Primary completion. 2025-12-12. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Survodutide 3.6 mg

Dose 3.6 mg

Regimen once weekly

Comparator placebo

Population Obesity; Diabetes Mellitus, Type 2

Survodutide 6.0 mg

Dose 6.0 mg

Regimen once weekly

Comparator placebo

Population Obesity; Diabetes Mellitus, Type 2

Placebo

Regimen once weekly

Population Obesity; Diabetes Mellitus, Type 2

ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease

Registry NCT07850063

Phase Phase 3

Status Not yet recruiting

Enrollment 600

Start 2026-11-02

Primary completion 2029-04-29

Study completion 2029-04-29

Catalyst Primary completion. 2029-04-29. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Survodutide arm

Regimen once weekly

Comparator placebo

Population Obesity; Metabolic Dysfunction-associated Steatotic Liver Disease

Placebo arm

Regimen once weekly

Population Obesity; Metabolic Dysfunction-associated Steatotic Liver Disease

SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight

Registry NCT07850050

Phase Phase 3

Status Not yet recruiting

Enrollment 600

Start 2026-10-31

Primary completion 2028-07-26

Study completion 2028-07-26

Catalyst Primary completion. 2028-07-26. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Survodutide arm

Regimen once weekly

Comparator placebo

Population Obesity

Placebo arm

Regimen once weekly

Population Obesity

SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

Registry NCT07855900

Phase Phase 3

Status Not yet recruiting

Enrollment 350

Start 2026-11-07

Primary completion 2029-11-06

Study completion 2029-11-06

Catalyst Primary completion. 2029-11-06. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

SWITCH cohort

Regimen once weekly

Population Obesity

INITIATION cohort

Regimen once weekly

Population Obesity

A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight

Registry NCT06214741

Phase Phase 3

Status Completed

Enrollment 307

Start 2024-02-06

Primary completion 2025-07-29

Study completion 2026-01-28

Catalyst Primary completion. 2025-07-29. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

survodutide 3.6 mg

Dose 3.6 mg

Regimen once weekly

Comparator placebo

Population Obesity; Overweight

survodutide 4.8 mg

Dose 4.8 mg

Regimen once weekly

Comparator placebo

Population Obesity; Overweight

Placebo

Regimen once weekly

Population Obesity; Overweight

SYNCHRONIZE™JP

Registry NCT06176365

Phase Phase 3

Status Completed

Enrollment 274

Start 2024-01-16

Primary completion 2025-12-03

Study completion 2025-12-03

Catalyst Primary completion. 2025-12-03. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Survodutide - 3.6 mg

Dose 3.6 mg

Regimen once weekly

Comparator placebo

Population Obesity

Survodutide - 6.0 mg

Dose 6.0 mg

Regimen once weekly

Comparator placebo

Population Obesity

Placebo group

Regimen once weekly

Population Obesity

A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Red

Registry NCT06309992

Phase Phase 3

Status Completed

Enrollment 218

Start 2024-04-02

Primary completion 2025-10-09

Study completion 2025-12-02

Catalyst Primary completion. 2025-10-09. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Treatment arm

Regimen once weekly

Comparator placebo

Population Obesity; Non-Alcoholic SteatoHepatitis (NASH)

Placebo arm

Regimen once weekly

Population Obesity; Non-Alcoholic SteatoHepatitis (NASH)

A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight

Registry NCT04667377

EudraCT 2020-002479-37

Phase Phase 2

Status Completed

Enrollment 387

Start 2021-03-08

Primary completion 2022-09-15

Study completion 2022-10-07

0.6 mg BI 456906

Dose 0.6 mg

Regimen once weekly

Weeks 46

Comparator placebo

Population Obesity

Estimand Efficacy

participants with at least 5 percent body weight loss, 60.7 %, week 46Stale

participants with at least 10 percent body weight loss, 33.9 %, week 46Stale

participants with at least 15 percent body weight loss, 12.5 %, week 46Stale

deaths

participants with diarrhoea, 22 participantsStale

participants with nausea, 36 participantsStale

participants with vomiting, 13 participantsStale

Placebo group

Regimen once weekly

Weeks 46

Population Obesity

Estimand Efficacy

participants with at least 5 percent body weight loss, 25.9 %, week 46Stale

participants with at least 10 percent body weight loss, 11.1 %, week 46Stale

participants with at least 15 percent body weight loss, 5.6 %, week 46Stale

deaths

participants with diarrhoea, 8 participantsStale

participants with nausea, 15 participantsStale

participants with vomiting, 4 participantsStale

2.4 mg BI456906

Dose 2.4 mg

Regimen once weekly

Weeks 46

Comparator placebo

Population Obesity

Estimand Efficacy

participants with at least 5 percent body weight loss, 81 %, week 46Stale

participants with at least 10 percent body weight loss, 65.5 %, week 46Stale

participants with at least 15 percent body weight loss, 37.9 %, week 46Stale

deaths

participants with diarrhoea, 21 participantsStale

participants with nausea, 60 participantsStale

participants with vomiting, 28 participantsStale

3.6 mg BI 456906

Dose 3.6 mg

Regimen once weekly

Weeks 46

Comparator placebo

Population Obesity

Estimand Efficacy

participants with at least 5 percent body weight loss, 82 %, week 46Stale

participants with at least 10 percent body weight loss, 65.6 %, week 46Stale

participants with at least 15 percent body weight loss, 45.9 %, week 46Stale

deaths

participants with diarrhoea, 17 participantsStale

participants with nausea, 45 participantsStale

participants with vomiting, 28 participantsStale

4.8 mg BI 456906

Dose 4.8 mg

Regimen once weekly

Weeks 46

Comparator placebo

Population Obesity

Estimand Efficacy

participants with at least 5 percent body weight loss, 82.8 %, week 46Stale

participants with at least 10 percent body weight loss, 68.8 %, week 46Stale

participants with at least 15 percent body weight loss, 54.7 %, week 46Stale

deaths

participants with diarrhoea, 9 participantsStale

participants with nausea, 32 participantsStale

participants with vomiting, 13 participantsStale

A Study to Test Different Doses of BI 456906 in Patients With Obesity

Registry NCT03591718

EudraCT 2018-000250-22

Phase Phase 1

Status Completed

Enrollment 131

Start 2018-07-26

Primary completion 2020-04-20

Study completion 2020-04-30

BI 456906

Comparator placebo

Population Obesity

Placebo

Population Obesity

A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity

Registry NCT06200467

Phase Phase 1

Status Completed

Enrollment 110

Start 2024-03-13

Primary completion 2025-10-22

Study completion 2025-10-22

Catalyst Primary completion. 2025-10-22. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Arm A: R1 then R3 then T then R

Regimen once weekly

Weeks 30

Comparator placebo

Population Overweight; Obesity

Arm B: R1 then R2 then R1 then R3

Regimen once weekly

Weeks 30

Population Overweight; Obesity

Arm C: R1 then R3 then R1 then R2

Regimen once weekly

Weeks 30

Population Overweight; Obesity

A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906

Registry NCT05751226

EudraCT 2022-002733-34

Phase Phase 1

Status Completed

Enrollment 88

Start 2023-04-11

Primary completion 2024-08-01

Study completion 2024-08-01

BI 1820237 treatment group

Regimen once weekly

Comparator placebo

Population Healthy; Obesity

Placebo group

Regimen once weekly

Population Healthy; Obesity

BI 1820237 + semaglutide treatment group

Regimen once weekly

Comparator placebo

Population Healthy; Obesity

placebo + semaglutide group

Regimen once weekly

Population Healthy; Obesity

BI 1820237 + BI 456906 treatment group

Regimen once weekly

Comparator placebo

Population Healthy; Obesity

placebo + BI 456906 group

Regimen once weekly

Population Healthy; Obesity

A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and With

Registry NCT05296733

EudraCT 2021-006247-10

Phase Phase 1

Status Completed

Enrollment 82

Start 2022-04-27

Primary completion 2023-12-29

Study completion 2023-12-29

Part A: BI 456906: Cohort 1

Regimen once weekly

Weeks 28

Population Healthy; Liver Diseases; Obesity

Part A: BI 456906: Cohort 2

Regimen once weekly

Weeks 28

Population Healthy; Liver Diseases; Obesity

Part A: BI 456906: Cohort 3

Regimen once weekly

Weeks 28

Population Healthy; Liver Diseases; Obesity

Part A: BI 456906: Cohort 4

Regimen once weekly

Weeks 28

Population Healthy; Liver Diseases; Obesity

Part B: BI456906: Cohort 1

Regimen once weekly

Weeks 28

Population Healthy; Liver Diseases; Obesity

Part B: BI456906: Cohort 2

Regimen once weekly

Weeks 28

Population Healthy; Liver Diseases; Obesity

Part B: BI456906: Cohort 3

Regimen once weekly

Weeks 28

Population Healthy; Liver Diseases; Obesity

A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity

Registry NCT06745284

Phase Phase 1

Status Active, not recruiting

Enrollment 64

Start 2025-03-26

Primary completion 2027-01-08

Study completion 2027-01-10

Catalyst Primary completion. 2027-01-08. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Survodutide arm

Regimen once weekly

Population Obesity

Semaglutide arm

Regimen once weekly

Population Obesity

A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-

Registry NCT07413913

Phase Phase 1

Status Completed

Enrollment 56

Start 2026-03-03

Primary completion 2026-05-28

Study completion 2026-06-11

Catalyst Primary completion. 2026-05-28. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Survodutide formulation A then Survodutide formulation B2

Population Healthy; Obesity

Survodutide formulation B2 then Survodutide formulation A

Population Healthy; Obesity

A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or Obesity

Registry NCT07768813

Phase Phase 1

Status Active, not recruiting

Enrollment 44

Start 2026-09-02

Primary completion 2026-12-08

Study completion 2026-12-22

Catalyst Primary completion. 2026-12-08. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

BI 456906 formulation A (Reference) then BI 456906 formulation B2 (Test)

Population Healthy; Obesity

BI 456906 formulation B2 (Test) then BI 456906 formulation A (Reference)

Population Healthy; Obesity

A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity

Registry NCT06564441

Phase Phase 1

Status Completed

Enrollment 34

Start 2024-10-01

Primary completion 2025-12-16

Study completion 2026-01-05

Catalyst Primary completion. 2025-12-16. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

All participants

Regimen once weekly

Population Overweight; Obesity

A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Blood

Registry NCT05896384

Phase Phase 1

Status Completed

Enrollment 32

Start 2023-12-21

Primary completion 2025-02-14

Study completion 2025-03-26

Catalyst Primary completion. 2025-02-14. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Microgynon® (Reference treatment (R)) followed by BI 456906 and Microgynon® (Test treatment (T))

Regimen weekly

Population Healthy

A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the Body

Registry NCT06492135

Phase Phase 1

Status Completed

Enrollment 30

Start 2024-08-12

Primary completion 2025-04-15

Study completion 2025-04-15

Catalyst Primary completion. 2025-04-15. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Arm 1: Participants with a body mass index (BMI) ranging from ≥27.0 kg/m² to ≤40.0 kg/m²

Regimen once weekly

Population Overweight; Obesity

Arm 2: Participants with a body mass index (BMI) ranging from ≥24.0 kg/m² to <27.0 kg/m²

Regimen once weekly

Population Overweight; Obesity

A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver

Registry NCT05202353

EudraCT 2021-000363-76

Phase Phase 1

Status Active, not recruiting

Enrollment 29

Start 2024-11-01

Primary completion 2027-01-06

Study completion 2027-02-03

Catalyst Primary completion. 2027-01-06. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Group 1: BI 456906

Regimen once weekly

Weeks 17

Population Obesity

Group 2: Semaglutide

Regimen once weekly

Weeks 17

Population Obesity

Group 3: BI 456906

Regimen once weekly

Weeks 17

Population Obesity

Group 4: Semaglutide

Regimen once weekly

Weeks 17

Population Obesity